Latest News and Press Releases
Want to stay updated on the latest news?
-
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
-
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.
-
Masonic Cancer Center, University of Minnesota to Present Human Data Readout for HCW9218 Phase 1 Study at SITC 2023
-
Presentation includes data on safety and dosage escalationand immune system reaction to HCW9218 No incidence of mucosal bleeding resulting from the HCW9218 TGF-β trap HCW9218 is one of the lead...
-
MIRAMAR, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...